226 related articles for article (PubMed ID: 24148573)
1. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.
Meijboom MJ; Pouwels KB; Luytjes W; Postma MJ; Hak E
Vaccine; 2013 Dec; 31(52):6254-60. PubMed ID: 24148573
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.
Meijboom MJ; Rozenbaum MH; Benedictus A; Luytjes W; Kneyber MC; Wilschut JC; Hak E; Postma MJ
Vaccine; 2012 Jun; 30(31):4691-700. PubMed ID: 22561315
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
4. The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.
Bos JM; Rietveld E; Moll HA; Steyerberg EW; Luytjes W; Wilschut JC; de Groot R; Postma MJ
Vaccine; 2007 Sep; 25(39-40):6922-9. PubMed ID: 17707959
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States.
Moghadas SM; Shoukat A; Bawden CE; Langley JM; Singer BH; Fitzpatrick MC; Galvani AP
Clin Infect Dis; 2024 May; 78(5):1328-1335. PubMed ID: 38035791
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM; van Ballegooijen M; Habbema JD
J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
[TBL] [Abstract][Full Text] [Related]
9. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
Shoukat A; Bawden CE; Röst G; LeBlanc JJ; Galvani AP; Langley JM; Moghadas SM
Vaccine; 2024 Mar; 42(7):1768-1776. PubMed ID: 38368226
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
Herring WL; Zhang Y; Shinde V; Stoddard J; Talbird SE; Rosen B
Vaccine; 2022 Jan; 40(3):483-493. PubMed ID: 34933763
[TBL] [Abstract][Full Text] [Related]
11. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
Bogaards JA; Coupé VM; Meijer CJ; Berkhof J
Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961
[TBL] [Abstract][Full Text] [Related]
12. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
14. Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
Do LAH; Le NTN; Mahmud S; Mulholland K; Pecenka C; Clark A
Vaccine; 2023 Nov; 41(46):6782-6790. PubMed ID: 37690873
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
Bilcke J; Marais C; Ogunjimi B; Willem L; Hens N; Beutels P
Vaccine; 2012 Jan; 30(3):675-84. PubMed ID: 22120193
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
17. RSV vaccine use--the missing data.
Drysdale SB; Sande CJ; Green CA; Pollard AJ
Expert Rev Vaccines; 2016; 15(2):149-52. PubMed ID: 26636902
[TBL] [Abstract][Full Text] [Related]
18. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].
Postma MJ; Heijnen ML; Beutels P; Jager JC
Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224
[TBL] [Abstract][Full Text] [Related]
19. [Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium].
De Graeve D; Verhaegen J; Ament A; Baltussen R
Acta Clin Belg; 2000; 55(5):257-65. PubMed ID: 11109640
[TBL] [Abstract][Full Text] [Related]
20. Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data.
Pouwels KB; Bozdemir SE; Yegenoglu S; Celebi S; McIntosh ED; Unal S; Postma MJ; Hacimustafaoglu M
PLoS One; 2016; 11(9):e0163567. PubMed ID: 27689356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]